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Choroidal neovascularization (CNV) is a severe eye disease that leads to blindness, especially in the elderly population. Various
endogenous and exogenous regulatory factors promote its pathogenesis. However, the detailed molecular biological mechanisms
of CNV have not been fully revealed. In this study, by using advanced computational tools, a number of key gene ontology (GO)
terms and KEGG pathways were selected for CNV. A total of 29 validated genes associated with CNV and 17,639 nonvalidated genes
were encoded based on the features derived from the GO terms and KEGG pathways by using the enrichment theory. The widely
accepted feature selection method—maximum relevance and minimum redundancy (mRMR)—was applied to analyze and rank
the features. An extensive literature review for the top 45 ranking features was conducted to confirm their close associations with
CNV. Identifying the molecular biological mechanisms of CNV as described by the GO terms and KEGG pathways may contribute
to improving the understanding of the pathogenesis of CNV.
1. Introduction
Choroidal neovascularization (CNV) is a serious eye disease
involving the abnormal growth of blood vessels in the choroid
region [1–3]. The growth originates from a break in Bruch’s
membrane, and subsequently the new blood vessels penetrate
into the subretinal pigment epithelium [4]. From an epidemi-
ological perspective, CNV is a major cause of pathological
visual loss in aging populations [5]. Clinically, age-related
macular degeneration (ARMD), myopia, and presumed ocu-
lar histoplasmosis syndrome (POHS) are the three major
pathogeneses attributed toCNV [6–8].TheWisconsin Beaver
Dam Eye Study [9] confirmed that up to 90% of visual loss in
ARMD is secondary to CNV. Given that ARMD is the most
common cause of visual loss in people older than 50 years,
CNV is speculated to be directly linked to such pathological
visual loss. Aside from ARMD, the other two pathological
processes—myopia [10] and POHS [11]—are also linked to
pathological visual loss.This finding validates the specific role
of CNV in pathological visual loss.
Clinically, most patients with CNV share a group of
characteristic signs and symptoms, including painless loss
of vision, metamorphopsia, paracentral or central scotoma,
and apparent changes in image size perception [12, 13]. Gen-
erally, patients with these complaints need further physical
examinations on blood, fluid, lipid exudation, and retinal
pigment epithelial detachment for accurate diagnoses [14].
However, for the final differential diagnosis, laboratory tests
are the golden criteria. Generally, the laboratory studies for
CNV involve three main techniques, namely, fluorescein
angiography [15], indocyanine green angiography [16], and
spectral domain optical coherence tomography [17]. For the
patients with confirmed diagnosis, due to the unclear patho-
logical mechanisms of CNV, anti-VEGF treatment that coun-
ters angiogenesis is the only preferred clinical therapeutic
approach [17]. However, the injection burden limits the long-
term application of such anti-VEGF treatment. Therefore,
more detailed pathological mechanisms of CNV need to be
revealed to promote the development and application of new
drugs against the disease.
Recent publications have partially revealed the detailed
pathological mechanisms of CNV, which involve the interac-
tions between genetic factors and exogenous environments.
For the environmental factors, the personal physical factors
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induced by the exogenous factors are directly involved in
the pathogenesis [18]. Age, obesity, high cholesterol, and
high blood pressure aggravate the progression of CNV and
further contribute to the occurrence of complications [19,
20]. Aside from these so-called physical exogenous factors,
various genetic factors are also connected to the initiation
and progression of CNV. Given that CNV is a highly specific
disease with an abnormal angiogenesis, genes associated with
angiogenesis, such as VEGF [21] and FGF2 [22], definitely
participate in the pathological processes, which have been
widely confirmed by reliable experiments. In addition to
these genes, a specific gene called CFI participates in CNV
and induces gradual visual loss and myopia; this finding is
based on the sequencing data of CNV families [23]. Further-
more, a specific study [24] on the East Asian population with
2119 patients and 5691 controls revealed a group of effective
hereditary and sporadic virulence genes that participate in
CNV, mapping out the detailed genetic blueprint of CNV.
Some trials were also conducted in the bioinformatics field.
Zhang et al. [25] presented a specific computational routine
for the identification of CNV-associated genes, indicating the
efficacy and accuracy of computational application in such
field.
As mentioned earlier, the genetic basis and the environ-
mental influences of CNV have been revealed. However, its
biological molecular mechanisms have not been explained
thoroughly. Here, the detailed biological processes, cellular
components, andmolecular functions that may participate in
the pathogenesis of CNVwere screened out by using compu-
tational methods. In this study, GO [26] and KEGG [26, 27]
pathways were introduced as two effective bioinformatics
tools to accurately describe such items [27]. Based on widely
known biological processes associated with CNV, an effective
network was rebuilt, and novel biological processes described
by the GO and KEGG items were screened out. Recent
publications have validated these highly correlative biological
processes, thus supporting the efficacy and accuracy of our
prediction. With the use of computational methods, a group
of functional biological processes that may participate in the
potential pathogenesis of CNVwere screened out, and for the
first time, the detailed pathologicalmechanisms of CNVwere
described at the level of comprehensive biological processes
instead of genes.The results contributed to the understanding
of the development and progression of CNV.
2. Materials and Methods
This study aimed to extract some key GO terms and KEGG
pathways that share close biological associations with CNV
by using a computational framework. The flowchart of our
method is illustrated in Figure 1 for the easy understanding
of this work.
2.1.Materials. In 2012, Newman et al. [28] reported a number
of genes that are related to AMD. We downloaded the
“Additional file 3” in their study [28], in which genes asso-
ciated with AMD in literature either by genetic linkage or as
expression biomarker were listed. Since CNV was a subtype
of AMD, we further filtered the genes. Only the genes in
29 genes
associated
with CNV
Other genes
Genes
20,983 GO and KEGG
features 
MaxRel feature list
Enrichment theory
45 key GO terms
mRMR method
MI value ≥ 0.003
Figure 1: Flowchart of selecting the key GO terms and KEGG
pathways related to CNV.
CNV Up or CNV Down modules from “Additional file 5”
in Newman et al.’s study were kept and at last, 35 CNV
genes were obtained. CNV Up or CNV Down modules were
generated by network clustering of differentially expressed
genes with a permuted 𝑝 < 0.1 and fold change ⩾ 1.5 among
31 normal, 7 MD1, 4 MD2, 17 Dry AMD, 2 GA, 4 CNV, and
3 GA/CNV samples. Therefore, the final CNV genes we used
were both reported by literature and differentially expressed.
The obtained 35 CNV genes were mapped onto their
Ensembl IDs.We excluded IDs that are not in the PPI network
reported in STRING (Version 10.0) [29]. 38 Ensembl IDs
were accessed. The GO terms and KEGG pathways were
used to investigate the difference between CNV-related genes
and others; thus, the Ensembl IDs without a GO term and
KEGG pathway information were excluded. A total of 29
Ensembl IDs were left. These IDs were the positive samples
in this study. The other 17,639 Ensembl IDs were the negative
samples and comprised the dataset together with the positive
samples in this study.The genes belonging to the positive and
negative samples are provided in Supplementary Material S1.
2.2. Feature Vector. The goal of this study was to refine
important GO terms and KEGG pathways that are associated
with CNV genes. To fulfill that goal, all the genes in the
dataset were needed to be represented by all the GO terms
and KEGG pathways. Here, the enrichment theory [30] of
the GO term and KEGG pathway was used to transform the
genes into numeric values, which indicated the biological
relationships between the genes and GO terms (KEGG
pathways). Comparing with the direct binary annotation of
whether a gene has a specific GO term or KEGG pathway,
the score obtained by the enrichment theory can indicate
the significance of overlap between a gene set and a GO or
KEGG function in the genome background. It is more robust
than the binary qualitative measurement [31]. To date, this
theory has been widely applied to investigate different gene-
or protein-related problems [30, 32–41]. After each gene was
represented by a larger number of features, by applying a
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feature selectionmethod described in Section 2.3, the keyGO
term orKEGGpathway features were extracted to distinguish
the difference between the positive and negative samples.The
encoding procedure follows.
GO Enrichment Score. The GO enrichment score was utilized
to represent the association between a GO term and an
involved gene as a numeric value. For a given GO term, such
as GO𝑗, and a gene 𝑔, the gene set𝐺1 consisted of genes anno-
tated to GO𝑗 and gene set 𝐺2 consisted of the neighbor genes
of 𝑔 in the protein–protein interaction network reported
in STRING (http://string-db.org/) [29], a well-organized
database providing known and predicted protein–protein
interactions. On the basis of the preceding items, the GO
enrichment score of GO𝑗 and 𝑔 can be defined as the −log10
of the hypergeometric test 𝑝 value [30, 32–35] of 𝐺1 and 𝐺2
according to the following equation:
ESGO (𝑔,GO𝑗) = −log10( 𝑛∑
𝑘=𝑚
(𝑀𝑘 ) (𝑁−𝑀𝑛−𝑘 )(𝑁𝑛 ) ) , (1)
where 𝑁 is the total number of genes in humans, 𝑀 is the
number of genes in 𝐺1, 𝑛 is the number of genes in 𝐺2,
and 𝑚 is the number of the common genes of 𝐺1 and 𝐺2.
A large enrichment score of GO𝑗 and 𝑔 indicated a close
relationship between them. In this study, 20,686 GO terms
were considered. Thus, 20,686 GO enrichment scores were
calculated for each gene in the dataset, which were obtained
by using an in-house program using R function phyper. The
R code is “score← −log10(phyper(numWdrawn − 1, numW,
numB, numDrawn, lower.tail = FALSE)),” where numW,
numB, and numDrawn correspond to the number of genes
annotated to GO𝑗, number of genes not annotated to GO𝑗,
and number of neighbor genes 𝑔, respectively.
KEGGEnrichment Score. Similar to theGO enrichment score,
the KEGG pathway score was calculated using the same
theory to represent the quantitative associations between the
KEGG pathways and genes in the dataset. For a given KEGG
pathway𝐾𝑗 and a gene 𝑔, 𝐺1 was a gene set containing genes
in𝐾𝑗 and𝐺2 had the samemeaning as described in preceding
paragraph. The KEGG enrichment score shared a similar
definition with the GO enrichment score between 𝐾𝑗 and 𝑔,
which was formulated as
ESKEGG (𝑔,𝐾𝑗) = −log10( 𝑛∑
𝑘=𝑚
(𝑀𝑘 ) (𝑁−𝑀𝑛−𝑘 )(𝑁𝑛 ) ) , (2)
where 𝑁,𝑀, 𝑛, and 𝑚 share similar definitions as described
in (1). In addition, a high score yielded by a KEGG pathway𝐾𝑗 and a gene 𝑔 indicated their strong associations. Here, 297
KEGG pathways were considered and resulted in 297 KEGG
enrichment scores for each gene, which were also obtained by
using an in-house program using R function phyper.
Accordingly, each gene in the dataset was encoded by
a combination of 20,686 GO term and 297 KEGG pathway
features and was defined as a feature vector with a total of
20,983 elements:
𝑓 (𝑔) = (ESGO (𝑔,GO1) , . . . ,ESGO (𝑔,GO20686) ,
ESKEGG (𝑔, 𝐾1) , . . . ,ESKEGG (𝑔, 𝐾291))𝑇 . (3)
2.3. Feature Selection. As described in Section 2.2, each gene
in the dataset was encoded with 20,983 features derived from
the GO terms and KEGG pathways. Some of them shared
closer biological associations with CNV.Thus, advanced tools
were necessary to extract these important features that played
essential roles in the development ofCNV.Here, a reliable and
widely accepted feature selectionmethod, namely, maximum
relevance and minimum redundancy (mRMR) [42], was
adopted to analyze all 20,983 features. The mRMR method,
proposed by Peng et al. [42], is a useful tool to analyze the
feature space of complicated biological problems. To date,
many investigations related to complicated biological systems
or problems have applied this method to analyze their feature
space and extract important information [34, 36, 43–52].
In the mRMR method, two excellent criteria were pro-
posed to rank the features: (1) maximum relevance and (2)
minimum redundancy. According to their names, the former
criterion measures the importance of features by relying on
their correlation to target variable, whereas the latter criterion
provides a guarantee that the selected features also have min-
imum redundancies. If one decides to construct an optimal
feature subspace, both maximum relevance and minimum
redundancy should be used. In this study, the purpose was
to extract important features that are closely related to CNV
rather than construct an optimal feature subspace.Therefore,
only the criterion of maximum relevance was employed to
rank the features in this study. The maximum relevance of
each feature was measured by the mutual information (MI)
between the feature and the target variable. For each feature,𝑓 was a variable representing the values in all samples and 𝑐
was the target variable. The MI was calculated as follows:
𝐼 (𝑐, 𝑓) = ∬𝑝 (𝑐, 𝑓) log 𝑝 (𝑐, 𝑓)𝑝 (𝑐) 𝑝 (𝑓)𝑑𝑐 𝑑𝑓, (4)
where 𝑝(𝑐) and 𝑝(𝑓) are the marginal probabilities of 𝑐 and 𝑓
and 𝑝(𝑐, 𝑓) is their joint probabilistic distribution. According
to (4), MI measures the mutual dependence between two
variables.
Based on the MI value assigned to each feature, the
feature ranking list called MaxRel feature list was obtained
and formulated as follows:
𝐹 = [𝑓1, 𝑓2, . . . , 𝑓𝑁] , (5)
where 𝑁 is the total number of features in the feature
space. A high rank received by a feature indicates a strong
association with CNV. Based on the properties of the top
ranked features, a new insight into the CNV can be proposed
for the investigation of the corresponding GO terms and
KEGG pathways.
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Figure 2: The number of selected features under different cut-offs
of MI values.
3. Results and Discussion
3.1. Results. As described in Section 2.2, a total of 20,983 GO
terms and KEGG pathway features were encoded in each
gene in dataset. Then, according to their relevance to the
target variables, these features were ranked in the descending
order by using themaximum relevance criterion described in
Section 2.3.The output feature list, called MaxRel feature list,
was built and obtained (Supplementary Material S2).
As mentioned in the preceding paragraphs, not all GO
terms or KEGG pathways shared equal roles on influenc-
ing the progression of CNV. Thus, extracting the key GO
terms or KEGG pathways was necessary. By applying the
maximum relevance criterion, all the features were ranked
by their relevance to the target variables, and the rank of a
corresponding feature in the output MaxRel feature list for
a GO term or KEGG pathway indicated its association with
CNV.According to theirMI values, someGO terms or KEGG
pathways received high MI values in the MaxRel feature
list; these features were extracted and their importance was
further investigated. To determine the cut-off of MI value,
a curve was plotted in Figure 2, which shows the number of
selected features under different cut-offs ofMI value. It can be
observed that the cut-off 0.003 was a proper choice, resulting
in 45 features.These features would be given further literature
review. Their detailed information is listed in Table 1. All
the 45 features corresponded to important GO terms. The
following section provides a detailed discussion on these GO
terms.
3.2. Analysis of Key GO Terms. As mentioned earlier, based
on our current computational methods, a group of func-
tional biological processes that may directly contribute to
the initiation and progression of CNV as a pathological
mechanism were screened out. In the prediction list, the top
45 biological processes described by the GO terms as optimal
CNV-associated biological processes were selected. Due to
the limitation of such manuscript, an individual analysis of
all the items was not feasible. Therefore, the top terms were
chosen, and their respective connection with CNV according
to recent publications was discussed. According to recent
publications, such GO terms can be summarized into three
major subgroups: angiogenesis, local neural metabolism,
and immune-associated biological processes. The detailed
discussion follows.
3.2.1. Analysis of Angiogenesis Associated Biological Processes.
The two GO terms in our prediction list—GO: 0031091
and GO: 0031093—both describe the functional cellular
components of platelet alpha-granules. In 2015, a specific
study [53] on proangiogenic responses confirmed that the
release of platelet alpha-granules promotes angiogenesis. No
direct connections were revealed between platelet alpha-
granules and CNV; however, abnormal angiogenesis plays an
irreplaceable role andmay be the core pathological biological
process during the initiation and progression of CNV [54].
Therefore, GO items associated with platelet alpha-granules,
such as cellular components GO: 0031091 and GO: 0031093,
are definitely associated with CNV. This result validated the
efficacy and accuracy of our prediction.
GO term GO: 0038133 describes a detailed pathway
called the ERBB2-ERBB3 signaling pathway. According to
recent publications, this signaling pathway contributes to
the regulation of cell survival and tumorigenesis [55, 56].
As for the detailed connections between the ERBB2-ERBB3
signaling pathway and CNV,mediated bymiR-199a andmiR-
125b, ERBB2 and ERBB3 as two functional components of
our predicted biological process have been confirmed to con-
tribute to the regulation of vascular endothelial growth factor
secretion and the stimulation of angiogenesis in multiple
tissues, including the eyes [57–59]. Given the core initiative
functions of angiogenesis for CNV, the predicted biological
process called the ERBB2-ERBB3 signaling pathway is a
potential CNV-associated GO term. Moreover, the next
predicted GO term, called GO: 0038129, also describes the
ERBB3-associated signaling pathway. This finding not only
implied the prediction consistency of the current computa-
tional methods but also further confirmed the specific role of
such pathways during the initiation and progression of CNV.
GO: 0031983 was the next predicted GO term and
describes the vesicle lumen as a functional cellular compo-
nent. As the parent term of GO: 0060205 describing the cyto-
plasmic vesicle lumen, such cellular component definitely is
associated with the initiation and progression of CNV. As for
detailed literature evidence, in 2009, a specific study on the
vascular permeability and pathological angiogenesis of CNV
confirmed that the vesicle lumen in living cells is related to the
vascular hyperpermeability and abnormal angiogenesis [60].
Vascular hyperpermeability [61] and abnormal angiogenesis
are both specific symptoms of CNV [62]; thus, such biological
processes are potential CNV-associated biological processes.
The next GO term, called GO: 0005576, describes a
general term called extracellular region. Various extracellular
substances participate in the pathogenesis of CNV, including
LOX [63], LOXL2 [63], Thy-1 [64], and integrins [65]. Such
specific substances may play irreplaceable roles during the
initiation and progression of CNV; thus, this GO term that
describes the extracellular regions of a certain focus is a
potential CNV-associated biological process. GO: 0035767,
as the next predicted GO in our prediction list, describes an
effective biological process called endothelial cell chemotaxis.
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Table 1: Top 45 key GO terms associated with CNV.
GO term ID GO term GO description MI value Rank
GO: 0031091 Platelet alpha-granule Cellular component 0.003 1
GO: 0031093 Platelet alpha-granule lumen Cellular component 0.003 2
GO: 0060205 Cytoplasmic membrane-bounded vesicle lumen Cellular component 0.003 3
GO: 0038133 ERBB2-ERBB3 signaling pathway Biological process 0.003 4
GO: 0038129 ERBB3 signaling pathway Biological process 0.003 5
GO: 1902847 Regulation of neuronal signal transduction Biological process 0.003 6
GO: 0061517 Macrophage proliferation Biological process 0.003 7
GO: 1902949 Positive regulation of tau protein kinase activity Biological process 0.003 8
GO: 0061518 Microglial cell proliferation Biological process 0.003 9
GO: 0031983 Vesicle lumen Cellular component 0.003 10
GO: 0005576 Extracellular region Cellular component 0.003 11
GO: 0035767 Endothelial cell chemotaxis Biological process 0.003 12
GO: 0002580 Regulation of antigen processing and presentation of peptide orpolysaccharide antigen via MHC class II Biological process 0.003 13
GO: 0044421 Extracellular region part Cellular component 0.003 14
GO: 0007603 Phototransduction, visible light Biological process 0.003 15
GO: 0001948 Glycoprotein binding Molecular function 0.003 16
GO: 0072562 Blood microparticle Cellular component 0.003 17
GO: 0044650 Adhesion of symbiont to host cell Biological process 0.003 18
GO: 0019062 Virion attachment to host cell Biological process 0.003 19
GO: 0010466 Negative regulation of peptidase activity Biological process 0.003 20
GO: 0009584 Detection of visible light Biological process 0.003 21
GO: 0010951 Negative regulation of endopeptidase activity Biological process 0.003 22
GO: 0001654 Eye development Biological process 0.003 23
GO: 0002581 Negative regulation of antigen processing and presentation of peptideor polysaccharide antigen via MHC class II Biological process 0.003 24
GO: 0052547 Regulation of peptidase activity Biological process 0.003 25
GO: 0052548 Regulation of endopeptidase activity Biological process 0.003 26
GO: 0005791 Rough endoplasmic reticulum Cellular component 0.003 27
GO: 0050839 Cell adhesion molecule binding Molecular function 0.003 28
GO: 0071307 Cellular response to vitamin K Biological process 0.003 29
GO: 1902430 Negative regulation of beta-amyloid formation Biological process 0.003 30
GO: 0005604 Basement membrane Cellular component 0.003 31
GO: 0030023 Extracellular matrix constituent conferring elasticity Molecular function 0.003 32
GO: 2000768 Positive regulation of nephron tubule epithelial cell differentiation Biological process 0.003 33
GO: 1903002 Positive regulation of lipid transport across blood brain barrier Biological process 0.003 34
GO: 1903000 Regulation of lipid transport across blood brain barrier Biological process 0.003 35
GO: 1903001 Negative regulation of lipid transport across blood brain barrier Biological process 0.003 36
GO: 1902951 Negative regulation of dendritic spine maintenance Biological process 0.003 37
GO: 1902999 Negative regulation of phospholipid efflux Biological process 0.003 38
GO: 1901627 Negative regulation of postsynaptic membrane organization Biological process 0.003 39
GO: 2001139 Negative regulation of phospholipid transport Biological process 0.003 40
GO: 0046911 Metal chelating activity Molecular function 0.003 41
GO: 0030574 Collagen catabolic process Biological process 0.003 42
GO: 0007423 Sensory organ development Biological process 0.003 43
GO: 0001968 Fibronectin binding Molecular function 0.003 44
GO: 0051346 Negative regulation of hydrolase activity Biological process 0.003 45
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Based on recent publications, such biological process is
involved in the activation of platelets [66] and exosome-
mediated antiangiogenesis [67]. Platelet activation [68] and
angiogenesis [69] are directly connected to the initiation and
progression of CNV; therefore, this predicted GO term is
quite significant in the pathogenesis of CNV.
3.2.2. Analysis of Local Neural Metabolism Associated Biolog-
ical Processes. GO: 0060205, as another cellular component
associated item, describes the cytoplasmic vesicle lumen.
Based on recent publications, such cellular component par-
ticipates in autophagy and secretion-associated biological
processes in living cells [70, 71]. As for the biological con-
nections between the cytoplasmic vesicle lumen and CNV,
the predicted GO-associated biological processes, such as
autophagy and substance secretion, have all been confirmed
to be involved in the initiation and progression of CNV
[72, 73]. This result implied the accuracy and efficacy of our
prediction.GO: 1902847 describes the regulation of neuronal
signal transduction. In the biological process of neuronal
signal transduction, a specific gene called IKK2 has been con-
firmed to be significant [74]. Coincidentally, the inhibition
of IKK2 has been widely used in the treatment against CNV,
indicating the specific role of IKK2 during the pathogenesis
of CNV [75, 76]. Therefore, connected by such functional
gene IKK2, the predicted biological processes associated
with neuronal signal transduction may also be related to
CNV. This finding validates the efficacy and accuracy of our
prediction. As the next predicted GO, GO: 1902949 describes
the positive regulation of tau protein kinase activity. Tau
protein is a major pathological factor that contributes to the
initiation and progression of Alzheimer’s disease (AD) [77–
79]. During the initiation and progression of AD, another
specific protein called apolipoprotein E4 (apoE4) interacts
with our predicted tau protein [80] and participates in the
pathogenesis of AD [81]. Given that recent studies also
validated the specific role of apoE4 in neovascularization
[82] and its potential functions in CNV [23], tau protein
associated kinase activity is reasonably connected to CNV-
associated biological characteristics.
3.2.3. Analysis of Immune-AssociatedBiological Processes. The
GO termGO: 0061517 describes the proliferation of a specific
immune-associated cell subgroup: macrophage. Based on
recent publications, macrophages contribute to CNV by
regulating CCR2-dependent and proangiogenic biological
processes [83, 84], indicating that the proliferation of such
gene is definitely related to the progression of the disease [85].
Apart from the proliferation of macrophage, the proliferation
of another effective cell subgroup called microglial cells is
also predicted to contribute to CNV by GO: 0061518 in our
prediction list. Mediated by neuroprotectin D1, microglial
ramifications and redistribution participate in the patho-
logical processes of CNV [86]. Therefore, as a functional
neuronal cell subtype with specific microglial ramifications
[86], this predicted GO is reasonably connected to CNV
[87]. Besides these predicted biological processes, several
functional GOs in the top 45 predicted GO terms have
been reported to participate in CNV-associated biological
processes. These functional GO terms include GO: 0002580
(regulation of antigen processing and presentation of peptide
or polysaccharide antigen via MHC class II) [88], GO:
0044421 (extracellular region) [89], and GO: 0007603 (pho-
totransduction, visible light) [90, 91].These results confirmed
the efficacy and accuracy of our prediction.
4. Conclusion
Based on our presented computational method, a group of
functional biological functions that have been confirmed by
recent publications to be related to the pathogenesis of CNV
were screened out. Such predicted biological processes not
only further revealed the detailed pathological mechanisms
of CNV but also provided a new tool to identify potential
functional disease-associated biological processes inmultiple
categories of the disease. Finally, we will try our best to
develop a computational method based on some extracted
features in this study to predict novel CNV genes in the
future.
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